Complexity Medium Added pathway GHRH, ghrelin receptor, GH, and IGF-1 Direct retatrutide stack trial None identified Main research question Could GH-axis signaling change body-composition research
Open questions heading into 2025 and beyond Important gaps remain
Specialized toxicology research shows no embryo-fetal developmental toxicity, no genetic mutagenicity in bacterial and mammalian cell assays, and no adverse reproductive effects in animal models
Week 1-2 Improved sleep quality, increased energy, possible water retention and joint stiffness Week 2-4 Enhanced exercise recovery, skin improvement, possible carpal tunnel symptoms Month 1-2 Noticeable fat loss (especially abdominal), improved skin elasticity and texture Month 2-3 Continued fat loss, lean mass improvements, hair/nail growth, reduced recovery time Month 3-6 Significant body composition changes, improved bone density, sustained energy/well-being Week 0-0 Maintained benefits
All items are for laboratory research use only